Chinese biotechs raised more than $1.5 billion in Q3, already more than double the amount raised in Q2 2025.
In September, VC has placed a bet on gene editing companies. CRISPR gene editing company YolTech raised $45 million in Series B funding led by the AstraZeneca-CICC Healthcare Investment Fund. The company’s CTO and co-founder Zi Jun Wang told Endpoints that YolTech will beat Intellia to pivotal data disclosure and approval.
Accuredit Therapeutics has secured $75 million in Series A funds to advance its gene editing therapy. The product ART001 became the first gene editing therapy in China to obtain RMAT designation from the FDA.
In addition, financing was aslo active in the field of in vivo cell therapy in September, including GRIT Biotechnology, Rui Therapeutics, Santo Therapeutics and Genocury Biotech.
Genfleet Therapeutics successfully listed on the Hong Kong Stock Exchange in September. The company has set up a highly differentiated RAS-targeted pipeline including selective and pan-RAS inhibitors of diverse molecular types to treat oncology and immunology.
Hengrui Pharma launched two deals last month, one with Braveheart Bio and the other with Glenmark Specialty.
Hengrui will receive $65 million upfront, $10 million in the near term, and up to $1.01 billion in biobucks, by selling the global rights to HRS-1893, a selective myosin inhibitor. In another collaboration with Glenmark Specialty, Hengrui will hand over certain rights to its HER2 antibody-drug conjugate trastuzumab, in exchange for $18 million upfront and up to $1.09 billion in regulatory and commercial milestones, plus sales-based royalties.
Argo Biopharmaceutical sighed the second agreement with Novartis for $160 million upfront and up to a whopping $5.2 billion in combined milestone payments and option fees. In January 2024, Argo was already entered a $4 billion biobuck pact with Novartis.
In the latest deal, Novartis will have first right of negotiation to an ANGPTL3-targeted candidate BW-00112, and the option for the ex-China rights for two discovery-stage molecules for severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.
